Update on clinically significant drug interactions in dermatology

Journal of the American Academy of Dermatology

Volumn 54, Issue 4, 2006, Pages 676-684

  Barranco, Vincent P ^a,b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

'HEMOCYTE'; ACICLOVIR; ADOXA; ALMOTRIPTAN; AMFEPRAMONE; AMIODARONE; AMITRIPTYLINE; AMNESTEEM; AMOBARBITAL; AMPICILLIN; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; APREPITANT; ARIPIPRAZOLE; ASENDIAN; ATAZANAVIR; ATORVASTATIN; BARBITURIC ACID DERIVATIVE; BENZATHINE PENICILLIN; BENZPHETAMINE; BUSULFAN; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CARBAMAZEPINE; CARBEX; CHLORPROMAZINE; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; CLOMIPRAMINE; CLOZAPINE; COMPRO; CONTRACEPTIVE AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DESIPRAMINE; DEXAMPHETAMINE; DICLOFENAC; DICLOFENAC POTASSIUM; DICLOXACILLIN; DIGITEK; DIGOXIN; DIHYDROERGOTAMINE MESILATE; DISOPYRAMIDE PHOSPHATE; DOCETAXEL; DOFETILIDE; DOXEPIN; DOXYCYCLINE; DULOXETINE; E BASE; ED IN SOL; ELETRIPTAN; EMYCIN; EPLERENONE; ERGOT DERIVATIVE; ERGOTAMINE TARTRATE; ERLOTINIB; ERY TAB; ERYTHROMYCIN; ESCITALOPRAM; ESGIC; ESOMEPRAZOLE; ETODOLAC; ETRETIN; FELODIPINE; FENOPROFEN CALCIUM; FERREX; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FIORNAL; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; FLUPHENAZINE; FLURBIPROFEN; FLUTICASONE PROPIONATE; FLUVOXAMINE MALEATE; FOSPHENYTOIN SODIUM; FROVATRIPTAN; GATIFLOXACIN; GEMIFLOXACIN; HEXACYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; HYTINIC; IBUPROFEN; IMATINIB; IMIPRAMINE; INDINAVIR; INDOMETACIN; IRON SACCHARATE; ISOCARBOXAZID; ISOTRETINOIN; ITRACONAZOLE; KETOCONAZOLE; KETOPROFEN; KETOROLAC; LANSOPRAZOLE; LEVACETYLMETHADOL; LEVOFLOXACIN; LEVOMEPROMAZINE; LOMEFLOXACIN; LOPINAVIR PLUS RITONAVIR; MACROLIDE; MARCILLIN; MARGESIC; MEFENAMIC ACID; MELOXICAM; MEPHENYTOIN; MESORIDAZINE BESYLATE; METHAMPHETAMINE; METHOTREXATE; METHYLPHENOBARBITAL; METICILLIN; MEVINOLIN; MINOCYCLINE; MOXIFLOXACIN; NAPROXEN; NARATRIPTAN; NEFAZODONE; NELFINAVIR; NEPHRO FER; NIFEDIPINE; NORFLOXACIN; NORTRIPTYLINE; NU IRON; OFLOXACIN; OLANZAPINE; OMEPRAZOLE; ONOXOL; ORUVIL; OXAPROZIN; PACLITAXEL; PANTOPRAZOLE; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PEGANONE; PENTOBARBITAL; PERPHENAZINE; PHENDIMETRAZINE TARTRATE; PHENELZINE; PHENOBARBITAL; PHENTERMINE; PHENTERMINE RESIN; PHENYTEK; PHENYTOIN; PHOSPHODIESTERASE V INHIBITOR; PIMOZIDE; PIPERACILLIN; PIROXICAM; PRAVASTATIN; PREDNISONE; PRELU 2; PRIMIDONE; PRO FAST; PROBENECID; PROCAINAMIDE; PROCAINE PENICILLIN; PROCHLORPERAZINE MALEATE; PROMACET; PROMAZINE; PROMETHAZINE; PROPIOMAZINE; PROTON PUMP INHIBITOR; PROTRIPTYLINE; QUINIDINE GLUCONATE; QUINIDINE SULFATE; RABEPRAZOLE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RISPERIDONE; RITONAVIR; RIZATRIPTAN; ROSUVASTATIN; SAQUINAVIR; SECBUTABARBITAL; SECOBARBITAL; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; SIMVASTATIN; SOLFOTON; SOLIFENACIN; SORTRET; SOTALOL; SPARFLOXACIN; STERAPRED; SULINDAC; SUMATRIPTAN SUCCINATE; TADALAFIL; TAXOID; TELITHROMYCIN; TERBINAFINE; TETRACYCLINE; TETRALAN; THIETHYLPERAZINE MALEATE; THIORIDAZINE; TICARCILLIN; TICLOPIDINE; TIZANIDINE; TOLMETIN; TRAMADOL; TRANYLCYPROMINE; TRIMIPRAMINE; TSUKUBAENOLIDE; UNINDEXED DRUG; VALACICLOVIR; VARDENAFIL; VERAPAMIL; VINBLASTINE SULFATE; VINCA ALKALOID; VINCRISTINE SULFATE; VITRON C; VORICONAZOLE; WARFARIN; ZOLMITRIPTAN;

DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG METABOLISM; DRUG MONITORING; ENZYME SUBSTRATE; HEART ARRHYTHMIA; HERB DRUG INTERACTION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

DERMATOLOGIC AGENTS; DRUG INTERACTIONS; HUMANS;

EID: 33645016220     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.01.003     Document Type: Review

References (26)

1. V.P. Barranco Update on clinically significant drug interactions in dermatology J Am Acad Dermatol 51 2004 e4
2. V.P. Barranco Clinically significant drug interactions in dermatology J Am Acad Dermatol 38 1998 599 612
3. V.P. Barranco Update on clinically significant drug interactions in dermatology J Am Acad Dermatol 46 2002 e7
4. D.S. Tatro Drug interaction facts St Louis: Facts and Comparisons 2000
5. P. du Souich In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol 8 2001 153 161
6. A. Hemeryck, and F.M. Belpaire Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update Curr Drug Metab 2 2002 13 37
7. D.S. Strettman, J.S. Bertino Jr., and A.N. Nafzier Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes Pharmacogenetics 10 2000 187 216
8. A. Sabers, J.M. Buchholt, P. Uldall, and E.L. Hansen Lamotrigine plasma levels reduced by oral contraceptives Epilepsy Res 47 2001 151 154
9. P.W. Azment, J.G. Bertolino, and J.L. Liszewski Clinically significant drug interactions Am Fam Physician 15 2000 1628 1637
10. G.K. Dresser, J.D. Spence, and D.G. Bailey Pharmacokinetics- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 2000 41 57
11. J. Van der Weide, Steijins, van Weelden, and K. de Haan The effects of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirements Pharmacogenetics 11 2001 287 291
12. R.R. Makkar, B. Fromm, R.T. Steinman, M.D. Meissner, and M.H. Lehman Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs JAMA 270 1993 2590 2597
13. M.H. Lehmann, S. Hardy, D. Archibald, B. Quart, and D.J. Macneil Sex difference in risk of torsades de pointes with d,l-sotalol Circulation 94 1996 2535 2541
14. D. Milou-Daniel, B.C. Knollmann, W.X. Wang, and R.L. Woosley Cardiac actions of erythromycin JAMA 280 1998 1774 1776
15. Y.G. Yap, and J. Camm Risk of torsades de pointes with non-cardiac drugs BMJ 320 2000 1158 1159
16. R.M. Seymour, and P.A. Routledge Important drug-drug interactions in the elderly Drugs Aging 12 1998 485 494
17. D.N. Juurlink, M. Mamdani, A. Kopp, A. Laupacis, and D. Redelmeier Drug-drug interactions among elderly patients hospitalized for drug toxicity JAMA 289 2003 1652 1658
18. Zithromax (azithromycin) [package insert] 2003 Pfizer Inc New York
19. D.E. Amacher, S.J. Shomaker, and J.A. Retsema Comparison of the effects of the new azalide antibiotic, azithromycin and erythromycin estolate on rat liver cytochrome P450 Antimicrob Agents Chemother 35 1991 1186 1190
20. J.W. Grunden, and K.A. Fisher Lovastatin induced rhabdomyolysis possibly associated with clarithromycin and azithromycin Ann Pharmacother 31 1997 859 863
21. B.R. Woldtvedt, C.L. Cahoon, L.A. Bradley, and S.J. Miller Possible increased anticoagulation effect of warfarin induced by azithromycin Ann Pharmacother 32 1998 269 270
22. D.R. Foster, and N.L. Milan Potential interaction between azithromycin and warfarin Pharmatherapy 19 1999 902 908
23. G.W. Amsden, O. Kuye, and G.C. We A study of interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers J Clin Pharmacol 42 2002 444 449
24. H. Lennernas Clinical pharmacokinetics of atorvastatin Clin Pharmacokinet 42 2003 1141 1160
25. K.L. McCall, H.G. Anderson Jr., and A.D. Jones Deterioration of lack of a drug interaction between azithromycin and warfarin Pharmacotherapy 24 2004 188 194
26. N.P. Beckey, D. Parra, and A. Colon Retrospective evaluation of a potential interaction between azithromycin and warfarin in patients stabilized on warfarin Pharmacotherapy 20 2000 1055 1059